

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e holman andrew/au

```

E1      1      HOLMAN ALBERT/AU
E2      1      HOLMAN ALEX H/AU
E3      1 -->  HOLMAN ANDREW/AU
E4      1      HOLMAN ANDREW J/AU
E5      1      HOLMAN ANDY/AU
E6      1      HOLMAN ARLENE J/AU
E7      5      HOLMAN B/AU
E8      1      HOLMAN B A/AU
E9      1      HOLMAN B J/AU
E10     8      HOLMAN B L/AU
E11     54     HOLMAN B LEONARD/AU
E12     13     HOLMAN B W/AU

```

=> s e3-5

```

      1 "HOLMAN ANDREW"/AU
      1 "HOLMAN ANDREW J"/AU
      1 "HOLMAN ANDY"/AU
L1      3 ("HOLMAN ANDREW"/AU OR "HOLMAN ANDREW J"/AU OR "HOLMAN ANDY"/AU)

```

=> d ti 1-3

```

L1  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
TI  Plastic film displays with NanoBlock IC drivers integrated by fluidic self
    assembly process

L1  ANSWER 2 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
TI  Administration of sleep restorative agents and efficacy of drug therapy

L1  ANSWER 3 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
TI  Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

```

=> analyze l1 2 ct

```

L2      ANALYZE L1 2 CT :      39 TERMS

```

=> d 1-39

```

L2      ANALYZE L1 2 CT :      39 TERMS

```

TERM #	# OCC	# DOC	% DOC	CT
1	11	1	100.00	DRUG DELIVERY SYSTEMS
2	8	1	100.00	INFLAMMATION
3	4	1	100.00	ARTHRITIS
4	2	1	100.00	AMYLOIDOSIS
5	2	1	100.00	ARTERY, DISEASE
6	2	1	100.00	BILIARY TRACT, DISEASE
7	2	1	100.00	CONNECTIVE TISSUE, DISEASE
8	2	1	100.00	PURPURA (DISEASE)
9	2	1	100.00	SPINAL COLUMN, DISEASE
10	1	1	100.00	ANEMIA (DISEASE)
11	1	1	100.00	ANTIBODIES AND IMMUNOGLOBULINS

12	1	1	100.00	AUTOIMMUNE DISEASE
13	1	1	100.00	BEHCET'S SYNDROME
14	1	1	100.00	BLOOD VESSEL, DISEASE
15	1	1	100.00	BRAIN, DISEASE
16	1	1	100.00	CORTICOSTEROIDS, BIOLOGICAL STUDIES
17	1	1	100.00	DERMATOMYOSITIS
18	1	1	100.00	FEVER AND HYPERTHERMIA
19	1	1	100.00	HEPATITIS
20	1	1	100.00	HUMAN
21	1	1	100.00	IMMUNOMODULATORS
22	1	1	100.00	INTERFERONS
23	1	1	100.00	KIDNEY, DISEASE
24	1	1	100.00	LEUKOCYTE
25	1	1	100.00	LUNG, DISEASE
26	1	1	100.00	LUPUS ERYTHEMATOSUS
27	1	1	100.00	MULTIPLE SCLEROSIS
28	1	1	100.00	MUSCLE, DISEASE
29	1	1	100.00	MYASTHENIA GRAVIS
30	1	1	100.00	MYOSITIS
31	1	1	100.00	RHEUMATIC DISEASES
32	1	1	100.00	RHEUMATOID ARTHRITIS
33	1	1	100.00	SARCOIDOSIS
34	1	1	100.00	SJOGREN'S SYNDROME
35	1	1	100.00	SKIN, DISEASE
36	1	1	100.00	SLEEP
37	1	1	100.00	THYROID GLAND, DISEASE
38	1	1	100.00	TRANSPLANT AND TRANSPLANTATION
39	1	1	100.00	TUMOR NECROSIS FACTOR RECEPTORS

***** END OF L2 ***

=> d his

(FILE 'HOME' ENTERED AT 10:56:16 ON 28 APR 2005)

FILE 'HCAPLUS' ENTERED AT 10:56:27 ON 28 APR 2005

E HOLMAN ANDREW/AU

L1 3 S E3-5

L2 ANALYZE L1 2 CT : 39 TERMS

=> d his

(FILE 'HOME' ENTERED AT 10:56:16 ON 28 APR 2005)

FILE 'HCAPLUS' ENTERED AT 10:56:27 ON 28 APR 2005

E HOLMAN ANDREW/AU

L1 3 S E3-5

L2 ANALYZE L1 2 CT : 39 TERMS

=> d ibib abs ind l1 2

L1 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:695785 HCAPLUS

DOCUMENT NUMBER: 137:210973

TITLE: Administration of sleep restorative agents and efficacy of drug therapy

INVENTOR(S): Holman, Andrew

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069974	A1	20020912	WO 2002-US6786	20020305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002165246	A1	20021107	US 2002-91744	20020305
PRIORITY APPLN. INFO.:			US 2001-273667P	P 20010305

OTHER SOURCE(S): MARPAT 137:210973

AB The present invention provides methods and compns. for increasing the efficacy of a therapeutic agent administered to a subject. A sleep restorative agent is co-administered to the subject along with the therapeutic agent, whereby the efficacy of the therapeutic agent is increased.

IC ICM A61K031-545
 ICS A61K031-47; A61K031-675

CC 1-11 (Pharmacology)

ST drug therapy efficacy sleep restorative agent

IT Hepatitis
 (C, arthritis; administration of sleep restorative agents and efficacy of drug therapy)

IT Arthritis
 (Reiter's syndrome; administration of sleep restorative agents and efficacy of drug therapy)

IT Amyloidosis
 Autoimmune disease
 Behcet's syndrome
 Connective tissue, disease
 Dermatomyositis
 Human
 Immunomodulators
 Multiple sclerosis
 Myasthenia gravis
 Rheumatoid arthritis
 Sarcoidosis
 Sjogren's syndrome
 Sleep
 (administration of sleep restorative agents and efficacy of drug therapy)

IT Corticosteroids, biological studies
 Interferons
 Tumor necrosis factor receptors
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (administration of sleep restorative agents and efficacy of drug

therapy)
 IT Inflammation
 Spinal column, disease
 (ankylosing spondylitis; administration of sleep restorative agents and efficacy of drug therapy)
 IT Artery, disease
 Inflammation
 (arteritis, temporal; administration of sleep restorative agents and efficacy of drug therapy)
 IT Brain, disease
 (autoimmune cerebritis; administration of sleep restorative agents and efficacy of drug therapy)
 IT Drug delivery systems
 (capsules; administration of sleep restorative agents and efficacy of drug therapy)
 IT Drug delivery systems
 (emulsions; administration of sleep restorative agents and efficacy of drug therapy)
 IT Amyloidosis
 (familial Mediterranean fever; administration of sleep restorative agents and efficacy of drug therapy)
 IT Fever and Hyperthermia
 (familial Mediterranean; administration of sleep restorative agents and efficacy of drug therapy)
 IT Transplant and Transplantation
 (graft-vs.-host reaction; administration of sleep restorative agents and efficacy of drug therapy)
 IT Anemia (disease)
 (hemolytic, autoimmune; administration of sleep restorative agents and efficacy of drug therapy)
 IT Kidney, disease
 (hemolytic-uremic syndrome; administration of sleep restorative agents and efficacy of drug therapy)
 IT Arthritis
 (hepatitis C; administration of sleep restorative agents and efficacy of drug therapy)
 IT Purpura (disease)
 (idiopathic thrombocytopenic; administration of sleep restorative agents and efficacy of drug therapy)
 IT Drug delivery systems
 (lozenges; administration of sleep restorative agents and efficacy of drug therapy)
 IT Antibodies and Immunoglobulins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal, immunosuppressive; administration of sleep restorative agents and efficacy of drug therapy)
 IT Rheumatic diseases
 (palindromic; administration of sleep restorative agents and efficacy of drug therapy)
 IT Drug delivery systems
 (parenterals; administration of sleep restorative agents and efficacy of drug therapy)
 IT Skin, disease
 (pemphigus vulgaris; administration of sleep restorative agents and efficacy of drug therapy)
 IT Artery, disease
 Inflammation

- (periarteritis nodosa; administration of sleep restorative agents and efficacy of drug therapy)
- IT Inflammation
Lung, disease
(pneumonitis, autoimmune; administration of sleep restorative agents and efficacy of drug therapy)
- IT Muscle, disease
(polymyalgia rheumatica; administration of sleep restorative agents and efficacy of drug therapy)
- IT Myositis
(polymyositis; administration of sleep restorative agents and efficacy of drug therapy)
- IT Drug delivery systems
(powders; administration of sleep restorative agents and efficacy of drug therapy)
- IT Biliary tract, disease
(primary biliary cirrhosis; administration of sleep restorative agents and efficacy of drug therapy)
- IT Arthritis
(pseudogout; administration of sleep restorative agents and efficacy of drug therapy)
- IT Arthritis
(psoriatic arthritis; administration of sleep restorative agents and efficacy of drug therapy)
- IT Inflammation
(pulmonary, autoimmune; administration of sleep restorative agents and efficacy of drug therapy)
- IT Leukocyte
(receptor, antibodies; administration of sleep restorative agents and efficacy of drug therapy)
- IT Connective tissue, disease
(scleroderma; administration of sleep restorative agents and efficacy of drug therapy)
- IT Biliary tract, disease
Inflammation
(sclerosing cholangitis; administration of sleep restorative agents and efficacy of drug therapy)
- IT Drug delivery systems
(solns.; administration of sleep restorative agents and efficacy of drug therapy)
- IT Spinal column, disease
(spondyloarthropathy; administration of sleep restorative agents and efficacy of drug therapy)
- IT Drug delivery systems
(suppositories; administration of sleep restorative agents and efficacy of drug therapy)
- IT Drug delivery systems
(suspensions; administration of sleep restorative agents and efficacy of drug therapy)
- IT Drug delivery systems
(syrups; administration of sleep restorative agents and efficacy of drug therapy)
- IT Lupus erythematosus
(systemic; administration of sleep restorative agents and efficacy of drug therapy)
- IT Drug delivery systems
(tablets; administration of sleep restorative agents and efficacy of drug therapy)

IT Purpura (disease)
 (thrombotic thrombocytopenic; administration of sleep restorative
 agents and efficacy of drug therapy)

IT Inflammation
 Thyroid gland, disease
 (thyroiditis, Hashimoto's; administration of sleep restorative agents
 and efficacy of drug therapy)

IT Drug delivery systems
 (transdermal, patches; administration of sleep restorative agents and
 efficacy of drug therapy)

IT Blood vessel, disease
 Inflammation
 (vasculitis; administration of sleep restorative agents and efficacy of
 drug therapy)

IT 50-18-0, Cyclophosphamide 53-03-2, Prednisone 59-05-2, Methotrexate
 446-86-6, Azathioprine 846-49-1, Lorazepam 1622-61-3, Clonazepam
 50924-49-7, Mizoribine 51322-75-9, Tizanidine 53123-88-9, Rapamycin
 60142-96-3, Gabapentin 75706-12-6, Leflunomide 79217-60-0, Cyclosporin
 82626-48-0, Zolpidem 89149-10-0, Deoxyspergualin 91374-21-9
 96187-53-0, Brequinar 104617-86-9 104632-26-0 104987-12-4, Ascomycin
 148553-50-8, Pregabalin 151319-34-5, Zaleplon 156679-34-4, Lenercept
 185243-69-0, Etanercept
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (administration of sleep restorative agents and efficacy of drug
 therapy)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	36.48	36.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'REGISTRY' ENTERED AT 11:02:03 ON 28 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2005 HIGHEST RN 849400-77-7
 DICTIONARY FILE UPDATES: 27 APR 2005 HIGHEST RN 849400-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****

```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

'ED' IS DEFAULT FORMAT FOR 'REGISTRY' FILE

=> e pramipexole/ct

'CT' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'REGISTRY'

The indicated field code is not available for EXPAND in this file. To see a list of valid EXPAND field codes, enter HELP SFIELDS at an arrow prompt (=>).

=> e pramipexole/cn

```

E1      1      PRAMINIL/CN
E2      1      PRAMINO/CN
E3      1 --> PRAMIPEXOLE/CN
E4      1      PRAMIPEXOLE DIHYDROCHLORIDE/CN
E5      1      PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE/CN
E6      1      PRAMIPEXOLE HYDROCHLORIDE/CN
E7      1      PRAMIRACETAM/CN
E8      1      PRAMIRACETAM HYDROCHLORIDE/CN
E9      1      PRAMIRACETAM SULFATE/CN
E10     1      PRAMITOL/CN
E11     1      PRAMITOL 5P/CN
E12     1      PRAMIVERIN/CN

```

=> s e3

```

L3      1 PRAMIPEXOLE/CN

```

=> d


```

L3      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN      104632-26-0  REGISTRY
ED      Entered STN:  11 Oct 1986
CN      2,6-Benzothiazolodiamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI)  (CA
        INDEX NAME)
OTHER CA INDEX NAMES:
CN      2,6-Benzothiazolodiamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-
OTHER NAMES:
CN      (-)-Pramipexole
CN      Pramipexole
CN      Sifrol
CN      SND 919
CN      SUD 919CL2Y
CN      U 98528E
FS      STEREOSEARCH
MF      C10 H17 N3 S
CI      COM

```

SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CIN, CSCHM, DDFU,
 DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,
 MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE,
 TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

305 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 306 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 11 Oct 1986

=> e pramipexole/cn

E1	1	PRAMINIL/CN
E2	1	PRAMINO/CN
E3	1 -->	PRAMIPEXOLE/CN
E4	1	PRAMIPEXOLE DIHYDROCHLORIDE/CN
E5	1	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE/CN
E6	1	PRAMIPEXOLE HYDROCHLORIDE/CN
E7	1	PRAMIRACETAM/CN
E8	1	PRAMIRACETAM HYDROCHLORIDE/CN
E9	1	PRAMIRACETAM SULFATE/CN
E10	1	PRAMITOL/CN
E11	1	PRAMITOL 5P/CN
E12	1	PRAMIVERIN/CN

=> s pramipexole/cn

L4 1 PRAMIPEXOLE/CN

=> file hcplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.33	49.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

FILE 'HCPLUS' ENTERED AT 11:03:48 ON 28 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2005 VOL 142 ISS 18

FILE LAST UPDATED: 27 Apr 2005 (20050427/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:56:16 ON 28 APR 2005)

FILE 'HCAPLUS' ENTERED AT 10:56:27 ON 28 APR 2005

E HOLMAN ANDREW/AU

L1 3 S E3-5

L2 ANALYZE L1 2 CT : 39 TERMS

FILE 'REGISTRY' ENTERED AT 11:02:03 ON 28 APR 2005

E PRAMIPEXOLE/CN

L3 1 S E3

E PRAMIPEXOLE/CN

L4 1 S PRAMIPEXOLE/CN

FILE 'HCAPLUS' ENTERED AT 11:03:48 ON 28 APR 2005

=> s 14

L5 306 L4

=>